The recommendation addresses a long-standing treatment gap for patients facing bladder removal after standard therapy fails.
Stars Insider on MSN
Bladder cancer: The signs, symptoms, and treatments
Bladder cancer is among the top 10 most common cancer types in the world, with approximately 573,000 new cases annually. Men ...
Providing surgeons feedback and education on their performance significantly improved the quality of bladder cancer ...
Shares of ImmunityBio ticked higher after the company said the European Medicines Agency recommended granting a conditional marketing authorization for its treatment for non-muscle invasive bladder ...
ImmunityBio (NASDAQ: IBRX), a leading immunotherapy company, announced today that the European Medicines Agency has ...
UI Health Care researchers designed a new device to improve convenience and quality of life for bladder cancer patients ...
A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...
Study Finds on MSN
Childhood Virus Linked To Bladder Cancer Decades Later
A virus carried by 95% of adults from childhood may trigger bladder cancer decades later by damaging cells during immune ...
The U.S. Food and Drug Administration has approved Pfizer's Padcev (enfortumab vedotin-ejfv), a Nectin-4 directed ...
Researchers have discovered that analyzing specific patterns of cell-free DNA (cfDNA) fragmentation in a simple urine sample ...
Further diagnostic tests revealed that Charles has “a form of cancer.” In the months since the announcement, no further ...
Investing.com -- ImmunityBio (NASDAQ:IBRX) stock rose 3.9% Friday after the European Medicines Agency (EMA) recommended granting conditional marketing authorization for its bladder cancer therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback